

The potential role of the Mediterranean Diet for the treatment and management of Polycystic Ovary Syndrome: a review of the pathophysiological mechanisms and clinical evidence

Nicole Scannell¹, Anthony Villani¹, Lisa Moran², Evangeline Mantzioris³

¹School of Health, University of the Sunshine Coast, QLD, Australia.

²Monash Centre for Health Research and Implementation (MCHRI), School of Public Health and Preventive Medicine, Monash University, VIC, Australia

³UniSA Clinical & Health Sciences, Alliance for Research in Exercise, Nutrition, and Activity (ARENA), University of South Australia, Australia

Correspondence: Dr Evangeline Mantzioris; UniSA Clinical & Health Sciences, ARENA, University of South Australia, Australia; phone: +61 8 830 22574; email: evangeline.mantzioris@unisa.edu.au



This is an Accepted Manuscript for Proceedings of the Nutrition Society. This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its

DOI 10.1017/S0029665124007584

Proceedings of the Nutrition Society is published by Cambridge University Press on behalf of The Nutrition Society.

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder amongst reproductive-aged women associated with cardiometabolic, reproductive and psychological abnormalities. Lifestyle modification, including a healthy diet, is considered first-line treatment for management of clinical symptoms. However, there is limited high-quality evidence to support one superior therapeutic dietary intervention for PCOS management that is beyond general population-based dietary guidelines. Adherence to a Mediterranean diet (MedDiet) has been shown to decrease cardiometabolic disease risk and attenuate depressive symptoms, particularly in patients with metabolic perturbations. This narrative review summarises the proposed biological mechanisms underpinning the potential therapeutic benefits of a MedDiet for the management of cardiometabolic, reproductive and psychological features related to PCOS. Observational evidence suggests an inverse relationship between MedDiet adherence and PCOS features, particularly insulin resistance and hyperandrogenemia. Although the exact mechanisms are complex and multifaceted, they are likely related to the anti-inflammatory potential of the dietary pattern. These mechanisms are underpinned by anti-inflammatory bioactive constituents present in the MedDiet, including carotenoids, polyphenols, and n-3 polyunsaturated fatty acids (PUFAs). Synthesis of the available literature suggests the MedDiet could be a promising therapeutic dietary intervention to attenuate short and long-term symptoms associated with PCOS and may aid in reducing the longer-term risks associated with cardiometabolic diseases and reproductive and psychological dysfunction. Nevertheless, current evidence remains insufficient to inform clinical practice and well-designed clinical trials are needed. As such, we provide recommendations for the design and delivery of future MedDiet interventions in women with PCOS, including exploring the acceptability, and feasibility to enhance adherence.

Keywords: Polycystic Ovary Syndrome, Mediterranean diet, insulin resistance, cardiometabolic, reproductive, psychological, anti-inflammatory

Introduction

Polycystic Ovary Syndrome (PCOS) is a common and heterogenous endocrine disorder, affecting approximately 8-13% of females of reproductive age ⁽¹⁾. It is a multifaceted syndrome characterised by a broad range of clinical symptoms, exerting both physical and psychological health-related consequences over the lifespan ^(2, 3). Diagnosis of PCOS typically includes a combination of medical history, the exclusion of other conditions with similar symptomology, clinical examination, and biological testing. The 2023 PCOS International Guidelines recommend that an adult diagnosis requires the presence of 2 of the 3 following features (with the exclusion of other causes); 1) oligo-/anovulation, 2) clinical or biochemical hyperandrogenism, 3) polycystic ovarian morphology identified via ultrasound or testing of anti-Mullerian hormone ⁽⁴⁾. In contrast, the recommended diagnosis for adolescent girls requires both oligo-/anovulation and clinical or biochemical hyperandrogenism, and excludes the testing of ovarian morphology ⁽⁴⁾.

Underpinning many of the negative consequences of PCOS is a reduction in insulin sensitivity coupled with high levels of androgens ^(2, 3, 5). Women with PCOS are at an elevated risk of developing a range of health complications, including type 2 diabetes mellitus (T2DM), metabolic syndrome ^(2, 6) and cardiovascular disease (CVD) ^(7, 8). Beyond these health concerns, PCOS significantly affects reproductive health, manifesting in symptoms such as infertility ⁽⁹⁾, irregular or absent menstrual cycles, and adverse neonatal and pregnancy outcomes including gestational diabetes, miscarriage and pre-eclampsia ⁽¹⁰⁻¹²⁾. The syndrome also has a notable impact on psychological health and wellbeing with an increased prevalence of disordered eating behaviours, including binge eating ^(13, 14) as well as heightened rates of anxiety and depression which negatively impacts health-related quality of life and self-efficacy ⁽¹⁴⁻¹⁷⁾. Although the mechanisms associated with insulin resistance (IR) in PCOS are largely independent of body weight, IR is still exacerbated by excess body weight ^(5, 18-20) and central adiposity, further heightening clinical symptoms and cardiometabolic risks ⁽²¹⁻²³⁾. Women with PCOS also have a greater propensity for longitudinal weight gain ^(21, 23). Therefore, weight loss and/or weight management is thought to be one of the most important therapeutic treatment strategies for the management of PCOS, and is typically the focus of many lifestyle interventions ⁽²⁴⁾. While weight loss improves many of the clinical features of PCOS ⁽²⁵⁾, it is important to appreciate that IR also affects women with PCOS who present within a healthy weight range (in accordance with normal BMI classifications) ⁽²⁶⁾. Therefore, as recommended in the international evidence-

based guidelines for management of PCOS, lifestyle modifications which include adopting a healthy dietary pattern coupled with regular physical activity are considered first-line treatment for both weight management and to better manage health outcomes associated with cardiometabolic disease risk, reproductive and psychological health⁽²⁷⁾. However, the optimal dietary approach remains controversial with limited high-quality evidence to support one specific dietary approach beyond traditional population-based dietary guidelines⁽²⁸⁻³⁰⁾. Nevertheless, dietary interventions which promote healthy long-term behaviour change, without necessarily focusing on weight loss and caloric restriction, may assist in improving psychological health⁽³¹⁾, and help facilitate adherence and maintenance to longer-term lifestyle and behavioural change. Therefore, to accommodate individual patient needs and health goals, defining the optimal dietary approach (with or without caloric restriction) for the management of PCOS is of clinical interest.

A Mediterranean diet (MedDiet), which is often described as an anti-inflammatory or plant-based dietary pattern, is typically characterised by a high consumption of fruits, vegetables, legumes, wholegrains and liberal use of extra-virgin olive oil (EVOO); moderate consumption of fermented dairy, eggs and red wine (consumed with meals only); and a low and/or infrequent consumption of red meat and meat products, butter, vegetable oils and processed foods⁽³²⁾. The traditional dietary pattern was first investigated among the people living in the olive growing regions of the Mediterranean basin before the mid-1960s. Nevertheless, because of the variability in cuisine and dietary constituents which define traditional dietary behaviours of inhabitants of the Mediterranean basin, a singular MedDiet does not exist⁽³³⁾. Nevertheless, despite potential differences in the operationalisation of a MedDiet, being predominantly plant-based, the dietary pattern is naturally low in ultra-processed foods, sugar and saturated fat and rich in several functional components, including vitamins and minerals, carotenoids, unsaturated fatty acids and phenolic compounds, depicted by antioxidant and anti-inflammatory properties⁽³⁴⁾.

There is substantial evidence supporting the efficacy of a Mediterranean diet (MedDiet) on cardiometabolic perturbations in other populations with similar risk profiles as those observed in PCOS. Specifically, adherence to a MedDiet is inversely associated with central obesity in epidemiological studies and is associated with weight loss, with or without caloric restriction, in dietary intervention studies^(35, 36). Moreover, adherence to a MedDiet has been shown to improve insulin sensitivity, glycemic control, and attenuate depressive symptoms, particularly in patients with metabolic perturbations⁽³⁷⁾. Nevertheless, evidence from well-

designed and robust clinical trials investigating the efficacy of a MedDiet to ameliorate PCOS symptoms is scant. However, evidence from well-designed and robust clinical trials investigating the efficacy of a MedDiet to ameliorate PCOS symptoms is scant. As such, this review aims to elucidate the proposed biological mechanisms underpinning the potential therapeutic benefits of a MedDiet for the management of features related to PCOS.

Features of PCOS

Cardiometabolic

The pathophysiology of cardiometabolic disease risk in PCOS is complex and multifaceted, involving interplays between hormonal imbalances, IR, chronic low-grade inflammation and obesity. IR is a hallmark feature of PCOS and occurs in at least 75% of cases, independent of body weight, resulting in impaired glucose metabolism⁽³⁸⁾. The proposed primary mechanism for IR in women with PCOS involves an increase in serine phosphorylation, causing post-binding defects in insulin signalling⁽³⁹⁾. Alternate mechanisms of IR include decreased glucose transporter 4 (GLUT4) in subcutaneous adipocytes, decreased hepatic clearance of insulin, mitochondrial dysfunction and activation of serine kinases in the mitogen-activated protein kinase/extracellular signal-regulated kinases (MAP-K) pathway⁽³⁹⁾. This subsequent hyperinsulinemia increases the risk of T2DM and is closely related to central obesity, dyslipidaemia and hypertension, forming a clustering of cardiometabolic abnormalities. Approximately 30% of women with PCOS have impaired glucose tolerance and 7.5% have T2DM⁽⁴⁰⁾ with the degree of risk to the onset of T2DM varying from between three to five-fold, contingent upon obesity and ethnicity⁽⁴¹⁾. Women with PCOS also exhibit an insulin paradox whereby ovarian and adrenal tissues remain sensitive to the stimulatory effects of insulin, despite displaying metabolic IR⁽⁴²⁾. Moreover, independent of IR, excess body weight, particularly central adiposity, also exacerbates metabolic and CVD risks by promoting dyslipidaemia, hypertension and a pro-inflammatory state, contributing to the formation and development of atherosclerosis and subsequent CVD risk^(43, 44). As such, the metabolic syndrome is also an important feature observed in PCOS⁽⁴⁵⁾.

Reproductive

The reproductive dysfunction observed in PCOS, encompassing irregular menstrual cycles, anovulation and subfertility, originate from an intricate interaction among hormonal dysregulation, IR and putative inflammatory pathways. Notably, PCOS emerges as the

principal aetiology of anovulatory infertility across the lifespan of the female ⁽⁴⁶⁾. Furthermore, infertility afflicts 70-80% of individuals diagnosed with PCOS ⁽⁴⁷⁾.

A common characteristic of PCOS is elevated levels of androgens ⁽⁴⁸⁾. While the precise physiological pathways remain elusive, prevailing evidence suggests that the ovaries and adrenal glands constitute the primary androgen sources in females ^(49, 50). In the ovaries, the synthesis of androgens is predominantly regulated by the ovarian theca cells, with contributions from the mesenchymal cells ⁽⁵¹⁾. However, PCOS is characterised by an abnormal androgen secretion, culminating in hyperandrogenism ⁽⁵²⁾. Hyperandrogenism can disrupt follicular growth and gene expression in oocytes, theca, and granulosa cells, potentially contributing to folliculogenesis complications and anovulation ⁽⁵³⁻⁵⁵⁾. In addition, IR and hyperinsulinemia can further escalate androgen levels, thereby intensifying hyperandrogenism and additionally impairing ovarian functionality.

Notably, the MAP-K insulin pathway remains unaffected by IR; rather, it is the compensatory hyperinsulinemia that augments androgen steroidogenesis in the thecal cells, thereby impeding follicular development ^(56, 57). The vicious cycle of obesity, IR and increased androgen production exacerbates hyperandrogenism ⁽⁵¹⁾. Women with PCOS exhibit a higher volume of visceral adipose tissue compared to their non-PCOS counterparts, which is positively correlated with total androgen levels ⁽⁵⁸⁾. Comparative analyses reveal that women who are overweight exhibit significantly elevated androgen levels relative to their healthy-weight peers ⁽⁵⁹⁾. Increased body weight correlates with reproductive dysfunction and lower oocyte quality, affecting implantation rates and oocyte retrieval during assisted reproduction, particularly in cases of central obesity ⁽⁶⁰⁻⁶²⁾.

Alterations in normal ovarian follicle development is also a hallmark feature in PCOS, with the ovaries developing numerous small, immature follicles that fail to progress to ovulation. ⁽⁶³⁾. This anomaly commonly termed 'polycystic ovaries', is observable via ultrasound and constitutes one of the diagnostic criteria for PCOS ⁽⁴⁾. Disrupted folliculogenesis leads to irregular or absent menstrual cycles (oligomenorrhea or amenorrhea), a defining feature of PCOS, and adversely affects fertility due to the lack of ovulation. This phenomenon is attributed to a dysregulated balance of pituitary gonadotrophins, with elevated luteinizing hormone (LH) to follicle stimulating hormone (FSH) ratio, resulting in an increase of androgens and decreased estrogen expression, culminating in disordered folliculogenesis, immature follicles, thus promoting infertility ⁽⁵¹⁾.

Chronic low-grade inflammation may also impair fertility by impeding oocyte maturation^(64, 65). Obesity, IR and hyperandrogenism are thought to collectively contribute to the pro-inflammatory state observed in women with PCOS⁽⁶⁶⁾. The follicular microenvironment, pivotal for ovarian function, is adversely affected by the presence pro-inflammatory cytokines including TNF- α , IL-1 β , IL-6⁽⁶⁷⁾. This low-grade inflammatory state within the follicular microenvironment may disrupt folliculogenesis by inducing oxidative stress in the ovaries^(68, 69) which is likely magnified by the presence of obesity⁽⁶⁹⁾.

Psychological

Women with PCOS have a heightened prevalence of depression (2.3-fold) and anxiety (4-fold) compared to those without PCOS⁽¹⁵⁾. The aetiology of these psychological disturbances remains unclear, implicating a multifactorial interplay among biological, psychological and socio-environmental determinants.

Neurotransmitter dysregulation observed in PCOS, specifically reduced inhibitory neurotransmitters such as serotonin, dopamine, gamma-aminobutyric acid, and acetylcholine, may disrupt the hypothalamic-pituitary-adrenal (HPA) axis and predispose individuals to depression^(70, 71). Concomitantly, an augmentation in neurotransmitters which elevate LH has been observed in PCOS, which could further precipitate depressive symptoms^(71, 72) by causing the theca cells in the ovary to produce excessive androgen and exacerbates the progression of PCOS⁽⁷³⁾. Moreover, hyperactivity of the HPA axis, observed in approximately 50% of major depressive disorder cases, contributes to depression through hypercortisolemia⁽⁷⁴⁾. Lastly, psychological stressors trigger an inflammatory response, increasing pro-inflammatory cytokines associated with depression and exacerbating PCOS symptoms⁽⁷⁵⁻⁷⁷⁾.

Although the exact mechanisms remain unclear, IR is another potential mediator, independently associated with depression in PCOS⁽⁷⁸⁾. Specifically, higher Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) scores correlate with a 2.3-fold increased risk of depression⁽⁷⁸⁾, possibly due to disruptions in insulin signalling affecting brain regions which influencing mood⁽⁷³⁾.

Clinical manifestations of PCOS, including hirsutism, acne, and alopecia, significantly impact self-esteem and body image⁽⁷⁹⁾, contributing to psychological distress such as depression, anxiety, and social phobia^(15, 80-83). Body dissatisfaction is also prevalent among

women with PCOS, exacerbated by the high prevalence of obesity in this clinical population, which also correlates with disordered eating behaviours, such as binge eating ⁽⁸⁴⁻⁸⁶⁾.

In addition, up to 70% of patients with PCOS experience infertility ⁽⁸⁷⁾, of which the clinical pregnancy rate using in vitro fertilization and embryo transfer technology is low ⁽⁸⁸⁾. Infertility treatments, such as in vitro fertilization, can exacerbate psychological distress through hormonal interactions impacting serotonin levels ⁽⁸⁹⁾.

Given the established role of PCOS as a predominate factor in infertility, this condition presents significant challenges to reproductive health and psychological well-being, contributing to psychosocial distress ⁽⁹⁰⁾ and negatively impacting health-related quality of life ⁽⁹¹⁾.

Potential benefits of a Mediterranean diet for the management of features related to PCOS. From evidence to proposed mechanisms

At present, the majority of the literature related to MedDiet adherence and features of PCOS are observational studies with relatively small samples (**Table 1**). Furthermore, many of these studies are conducted within Mediterranean populations where adherence to the diet is expected to be greater relative to non-Mediterranean populations, thus limiting the generalizability of the study findings. Nevertheless, there is evidence from Mediterranean populations showing low to moderate adherence to a MedDiet in recent years ⁽⁹⁵⁾. However, whether this reflects a true decrease in adherence given the absence of a universally accepted adherence tool and the marked heterogeneity and psychometric properties of each of the available adherence tools is unknown ⁽⁹⁶⁾. At present there are a number of diet quality indices used to quantify MedDiet adherence ⁽⁹⁷⁾, therefore making comparisons between studies challenging. For example, dietary adherence tools such as the alternate Mediterranean Food Score (MED) or the original Mediterranean Diet Score (MDS) are dependent on the usual dietary characteristics of the studied population and may not reflect true adherence to a traditional MedDiet, particularly in non-Mediterranean populations. Furthermore, adherence tools that are based on normative criteria and reflective of a traditional MedDiet, such as the Mediterranean Diet Adherence Screener (MEDAS) are also not without limitations, particularly when applied in non-Mediterranean populations given that it was developed and validated for application in Spanish middle-aged and older adults (aged 55–80 years) at a high risk of coronary heart disease, thus potentially limiting its utility and generalizability ⁽⁹⁸⁾.

Nevertheless, the absence of well-designed published clinical trials exploring the efficacy of a MedDiet intervention in women with PCOS represents an important gap in the research literature. In one of the only published randomised controlled trials, Mei et al ⁽⁹⁹⁾ showed that an energy-restricted low carbohydrate Mediterranean-style diet was superior in restoring menstrual regularity, lowering body weight, waist circumference and improving fasting blood glucose, insulin sensitivity, blood lipids, total testosterone and luteinizing hormone when compared against an energy-restricted low-fat diet in $n = 59$ Chinese women with PCOS and overweight or obesity. Although these results are indeed promising, irrespective of being identified as a Mediterranean-style diet, the dietary protocol described in the aforementioned study was not reflective of a Mediterranean-style diet. For example, MedDiet principles (e.g., high intake of fruits, vegetables, legumes, nuts and EVOO) were combined with a low-carbohydrate diet, consisting of less than 100 grams per day. Moreover, the dietary intervention was also calorie restricted. As such, it is plausible that any potential benefits observed may have been attributable to the caloric restricted, low carbohydrate component of the intervention, thus diluting any potential mechanistic benefit of the MedDiet. In general, dietary interventions targeted for women with PCOS and overweight or obesity are typically designed to create a caloric deficit to elicit weight loss. However, achieving caloric restriction and weight loss targets in this cohort is challenging, when compared to women without PCOS ⁽¹⁰⁰⁾. Although achieving clinically significant weight loss (e.g., $\geq 5\%$ of body weight) over short intervention periods has been documented in PCOS, attrition rates are almost 50% suggesting difficulties with adhering to calorie restricted diets ⁽¹⁰¹⁻¹⁰³⁾. Lastly, few studies investigate the potential benefits of a MedDiet on psychological outcomes in women with PCOS. Foscolou et al ⁽¹⁰⁴⁾ showed that a personalised MedDiet intervention, when compared against a standard lifestyle intervention, attenuated symptoms of anxiety in adolescent females with PCOS; however, to the best of our knowledge, this has yet to be thoroughly investigated in adult women.

Individual food groups and /or biologically active dietary constituents consistent with a MedDiet and their potential impact on cardiometabolic, reproductive and mental health have previously been reviewed ⁽¹⁰⁵⁻¹⁰⁷⁾. However, given the synergistic relationship of nutrients within the complex matrices of an existing dietary pattern, several physiological mechanisms connecting MedDiet adherence with clinical features of PCOS are likely. Therefore, the evidence related to MedDiet adherence and cardiometabolic, reproductive and psychological outcomes, and their proposed mechanisms, will be summarised herein.

Evidence from cardiometabolic outcomes

In the PREvención con DIeta MEDiterránea (PREDIMED) study, Estruch et al ⁽¹⁰⁸⁾ reported a 30% risk reduction in major cardiovascular events over a 5-year period in patients at high risk of cardiovascular disease when assigned to either a MedDiet supplemented with EVOO (1 litre/week) or nuts (30 grams/day), compared to those assigned to a low-fat control diet. Furthermore, after 4 years of follow-up, participants assigned to either of the two MedDiets, without caloric restriction, had a 40% and 18% reduction, respectively, in the incidence of T2DM compared to those in the low-fat control diet ⁽¹⁰⁹⁾. Investigators from the CORonary Diet Intervention with Olive oil and cardiovascular PREvention (CORDIOPREV) study assessed the effects of a MedDiet versus a low-fat control on endothelial function (as assessed by FMD) in patients with established coronary heart disease ⁽¹¹⁰⁾. Yubero-Serrano et al ⁽¹¹¹⁾ reported that patients assigned to the MedDiet intervention had higher FMD and endothelial progenitor cells and decreasing endothelial microparticles, regardless of the severity of endothelial dysfunction. Moreover, the investigators also showed that adherence to a MedDiet intervention decreased intracellular ROS production, cellular apoptosis, and endothelial cell senescence and increased cellular proliferation and angiogenesis.

Using a randomized cross-over study, Galie et al ⁽¹¹²⁾ assessed changes in plasma metabolites after following a MedDiet compared to the consumption of a singular healthy food (nuts) within the context of a non-MedDiet among participants with the metabolic syndrome. The investigators showed that adherence to a MedDiet, rather than consuming nuts in the context of a non-MedDiet, was significantly associated with changes in circulating metabolites (in particular lipids, acylcarnitines, amino acids, steroids and TCA intermediates); importantly these changes were also related to improvements in participants' metabolic risk profile, independent of changes in body weight, including decreases in fasting glucose, insulin and HOMA-IR. Esposito et al ⁽¹¹³⁾ reported that after 2 years of follow-up, participants with the metabolic syndrome randomized to receive a MedDiet (without energy restriction) showed significant improvements in endothelial function and reduced markers of systemic vascular inflammation, independent of changes in body weight, compared to those randomized to a standard healthy diet congruent with dietary guidelines. In contrast, Salas-Salvado et al ⁽¹¹⁴⁾ reported significant improvements in cardiovascular disease risk factors including waist circumference, fasting glucose, insulin sensitivity, triglycerides and HDL cholesterol in participants enrolled in the PREDIMED-Plus lifestyle intervention, aimed at evaluating the effect of an energy-restricted MedDiet intervention, physical activity promotion and

behaviour modification in overweight and obese middle-aged adults with the metabolic syndrome.

Similar improvements in metabolic risk profiles have also been observed in people with existing T2DM. When compared against participants habitual diet, Itsiopoulos et al ⁽¹¹⁵⁾ showed that a 12-week *ad libitum* MedDiet intervention was associated with significant reductions in HbA1c levels. In patients newly diagnosed with T2DM, Esposito et al ⁽¹¹⁶⁾ showed that a lower carbohydrate MedDiet resulted in greater reductions in HbA1c levels and delayed the need for diabetes medications by ~2 years compared with a standard low-fat diet. Moreover, this effect was largely independent of weight loss. In sub-group analysis from the CORDIOPREV study, Gutierrez-Mariscal et al ⁽¹¹⁷⁾ reported that in newly diagnosed diabetic patients with coronary heart disease, long-term (5 years) consumption of a MedDiet intervention was associated with improved glycemic control and a higher probability of T2DM remission.

Evidence from fertility outcomes

Research showing that maternal preconception dietary behaviours may be related to fertility, as well as influence IVF outcomes, including oocyte and embryo quality, implantation and successful completion of pregnancy ⁽¹¹⁸⁾. Nevertheless, there is a paucity of evidence to support specific dietary patterns or guidelines to improve fertility outcomes for women with much of the evidence linking diet to fertility largely based on studies of single nutrients, or individual food groups as opposed to whole dietary patterns, particularly for women undertaking IVF ⁽¹¹⁹⁾. Moreover, much of this evidence is limited to observational study designs. In a prospective cohort study of $n = 244$ women without obesity (aged 22–41 years) undergoing a first IVF treatment, Karayiannis et al ⁽¹²⁰⁾ reported that greater adherence to a MedDiet was associated with ~2.7 times higher likelihood of clinical pregnancy and live birth. Similar findings were also reported in a prospective cohort of women without obesity ($n = 357$) who underwent a total of 608 ART cycles, with the investigators reporting that women in the second and third quartiles of MedDiet adherence had higher probability of clinical pregnancy and live birth compared with women in the first quartile ⁽¹¹⁹⁾. In a further observational study of $n = 700$ Chinese women about to commence IVF, greater adherence to a MedDiet was positively associated with greater embryo yield ⁽¹²¹⁾. However, not all studies have described positive associations between MedDiet adherence and successful IVF outcomes, including clinical pregnancy, live birth, oocyte yield and embryo quality ^(122, 123).

The menstrual cycle is also an important indicator of reproductive health and irregular menstrual cycles may indicate anovulation, and thus decrease the ability to conceive⁽¹²⁴⁾. In a cross-sectional analysis of $n = 311$ Spanish female university students, Onieva-Zafra et al⁽¹²⁵⁾ reported that women with low adherence to a MedDiet had longer menstrual cycles than those with higher adherence. Moreover, upon further analysis of individual constituents of a MedDiet, women who consumed less than two pieces of fruit per day were more likely to suffer from menstrual pain; similar findings were also observed for women who infrequently consumed legumes (≤ 1 time per week)⁽¹²⁵⁾.

Evidence from psychological outcomes

An increasing body of evidence has emerged suggesting that diet quality may be an important modifiable risk factor for mental health disorders. In particular, evidence from systematic reviews and meta-analyses suggests that adherence to MedDiet is inversely associated with a risk of depression or depressive symptoms in both younger and middle-aged adults^(126, 127). In addition to the growing body of observational research, the SMILES⁽¹²⁸⁾ and HELFIMED⁽¹²⁹⁾ studies were among the first two clinical trials to show that a MedDiet intervention can be effective at reducing depressive symptoms in adults with major depression or mild depressive symptoms. These findings have since been corroborated in a recent systematic review and meta-analysis of clinical trials⁽¹³⁰⁾. Nevertheless, given the between study heterogeneity, the investigators suggested a need for more robust, long-term RCTs in order to establish recommendations in clinical practice.

Potential therapeutic benefits of a Mediterranean Diet

Although the exact mechanisms by which a MedDiet exerts potential benefits on improving clinical features of PCOS remains to be elucidated, it is likely related to the anti-inflammatory potential of the dietary pattern, reductions in oxidative stress and a higher intake of antioxidants derived from the dietary pattern, as depicted in **Figure 1**. The apparent anti-inflammatory benefits of a MedDiet have been shown in a number of clinical trials, including sub-group analysis of the PREDIMED study where adherence to both MedDiet intervention groups downregulated the expression of adhesion molecules on circulating T lymphocyte and monocyte surfaces, as well as inflammatory biomarkers (TNF- α , IL-6, MCP-1, and CRP) in serum⁽¹³¹⁻¹³⁵⁾. As such, there is now a large body of evidence from observational and intervention studies that have identified an inverse relationship between

plant-based dietary patterns and oxidative stress and proinflammatory biomarkers ⁽¹³⁶⁻¹³⁹⁾. This is not surprising given that the MedDiet is predominantly plant based and contain numerous anti-inflammatory constituents which may displace other dietary or food components (e.g., saturated fat, sugar and ultra-processed foods) which are known to elicit chronic inflammation and chronic disease. For example, flavonoids are biologically active polyphenolic compounds ubiquitously found in plant-based foods with antioxidant and anti-inflammatory effects ^(140, 141). Furthermore, carotenoids and polyphenols both act as potent scavengers of ROS, inhibit lipid peroxidation and modulate redox-sensitive transcription factors involved in the up-regulation of pro-inflammatory cytokines ^(142, 143). Specifically, they suppress proinflammatory molecules and modulate inflammatory pathways, including NF- κ B, AMP-activated protein kinase (MAPK) and the arachidonic acid pathway ⁽¹⁴¹⁾. For examples, polyphenols from EVOO, the principal lipid source in a MedDiet, blunts pro-oxidant enzymes NOX-2 and NOX-4 and increases the expression of anti-inflammatory molecules including peroxisome proliferator-activated receptor- γ (PPAR γ) mRNA ⁽¹⁴⁴⁾. Moreover, EVOO polyphenols also attenuate TNF- α -induced NF- κ B activation and thus elicits a protective function on the endothelium, therefore protecting against arteriosclerosis and major cardiovascular events ⁽¹⁴⁵⁾. In addition, previous literature has shown that higher intakes of soluble fibre can modulate inflammatory responses in response to the production of short-chain fatty acids, in particular butyrate, which is involved in the activation of transcription factors which modulate the expression of genes encoding proinflammatory cytokines ⁽¹⁴⁶⁻¹⁴⁸⁾. Dietary antioxidants, in particular vitamins C and E are potent free radical scavengers where there is cross-sectional evidence showing an inverse association with pro-inflammatory cytokines ^(149, 150). Moreover, several systematic reviews have been published regarding the role of omega-3 polyunsaturated fatty acids (n-3 PUFA), a key lipid source within a MedDiet ⁽¹⁵¹⁾, on ameliorating inflammatory biomarkers in patients' chronic diseases ^(152, 153). In particular, the long chain marine n-3 PUFA fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) partially inhibit a number of key aspects of inflammation including leucocyte chemotaxis, expression of adhesion molecules and leucocyte-endothelial adhesive interactions, production of eicosanoids and the up-regulation of pro-inflammatory cytokines, including TNF- α and IL-6 ^(154, 155). Often interlinked, the proposed anti-inflammatory actions of marine n-3 PUFAs include altering the phospholipid fatty acid composition of cell membranes, inhibition of the pro-inflammatory transcription

factor nuclear factor kappa B and activation of the anti-inflammatory transcription factor peroxisome proliferator activated receptor γ ⁽¹⁵⁶⁾.

Higher intakes of unsaturated fats (e.g., EVOO, nuts and fatty fish) have been associated with increased insulin sensitivity and improved beta cell function ⁽¹⁵⁷⁾. Specifically, bioactive compounds from EVOO (e.g., polyphenols) and marine n-3 PUFAs (e.g. EPA and DHA) act in the gastrointestinal tract to improve postprandial insulin release and sensitivity through increases in glucagon-like-peptide-1 (GLP1) expression from endocrine L-cells, which stimulates insulin secretion and inhibits glucagon secretion ⁽¹⁵⁷⁻¹⁵⁹⁾. Moreover, EPA and DHA have also been shown to increase insulin sensitivity by altering the concentrations of adipokines including leptin, adiponectin, resistin and visfatin; increasing the expression of GLUT-4 and producing anti-inflammatory effects to increase glucose uptake ⁽¹⁵⁷⁾. Lastly, it is well documented that dietary flavonoids present in plant foods, in particular quercetin, hesperidin and anthocyanins possess anti-diabetic properties including enhancing the function of glucose transporters, reducing metabolic stress in mitochondria, improved beta cell functioning and attenuation of oxidative stress in response to inflammation in tissues including muscle, liver and adipose ⁽¹⁶⁰⁻¹⁶²⁾.

The proposed mechanisms whereby anti-inflammatory properties of a MedDiet and the influence on outcomes related to fertility, although largely unclear, have previously been reviewed by members of our team ⁽¹⁶³⁾. For example, excess ROS coupled with a low intake of dietary antioxidants results in oxidative stress. Chronic oxidative stress can cause lipid peroxidation of cell membranes and subsequent DNA damage in functioning cells of the reproductive system ⁽¹⁶⁴⁾ which may help to explain how adherence to a MedDiet may enhance female fertility and IVF success rate. Moreover, a higher folate intake may increase the number of oocyte and embryo by facilitating DNA methylation ⁽¹⁶⁵⁾. With respect to menstrual parameters, pro-inflammatory mediators including PGF2- α and PGE2, which are associated with inflammation, play a role in dysmenorrhea ⁽¹⁶⁶⁾. These prostaglandins cause pain by increasing contractions in the uterus and are also involved in enhancing vasoconstriction, thereby controlling local hypoxia and smooth muscle contraction and the production of anaerobic metabolites ⁽¹⁶⁶⁾. It has been postulated that marine n-3 PUFAs can ease menstrual pain and dysmenorrhea by inhibiting arachidonic acid metabolism and suppressing the production of pro-inflammatory prostaglandins that are implicated in dysmenorrhoea ⁽¹⁶⁷⁾ with its potential efficacy supported by findings from systematic reviews and meta-analyses ^(168, 169).

A number of proposed mechanisms have been discussed to help explain the interplay between adherence to a MedDiet and risk of depression ⁽¹⁷⁰⁾. The most compelling related to the anti-inflammatory bioactive constituents of a MedDiet (e.g., carotenoids polyphenols and n-3 PUFAs) together with vitamins and trace minerals with antioxidant properties which can attenuate key biological mechanisms (e.g., oxidative stress and inflammation) related to depression ⁽¹⁷⁰⁾. Phenolic compounds in particular may play an important role due to their ability to protect neurons from oxidative stress and the interplay with nitric oxide to reduce inflammation and protect the vascular endothelium ^(171, 172). Other plausible mechanisms include normalizing neurotransmitter production, HPA axis function and glucocorticoid receptor signalling, all of which are altered with depression ^(173, 174). Lastly, key dietary constituents of a MedDiet, namely nuts and legumes, which are rich in dietary fibre, unsaturated fatty acids and bioactive compounds (e.g., antioxidants and polyphenols), elicit a favourable prebiotic effect on the gut microbiota composition and the production of anti-inflammatory metabolites, such as butyrate ⁽¹⁷⁵⁾.

Transferability and feasibility of a Mediterranean dietary pattern. Can it be followed in non-Mediterranean populations?

Whether the MedDiet, or at least principles of a MedDiet, can be followed in non-Mediterranean countries is up for debate and an emerging area of research. Nevertheless, due to its proposed health benefits, the translation of a MedDiet to non-Mediterranean populations is appealing and warrants ongoing research. Two previous feasibility studies conducted in Australia showed that participants generally felt confident in their capabilities of long-term adherence ^(176, 177). Similar findings have also been observed in the UK ^(178, 179). Furthermore, members of our team have previously reviewed the literature on the efficacy and adherence of a MedDiet used as a dietary intervention in clinical trials conducted in Australia against primary outcomes related to cardiometabolic risk factors, glycaemic control, cognition, hepatic steatosis and depressive symptomology ⁽¹⁸⁰⁾. Although long-term adherence was achievable, this was not without the inclusion of one-on-one and frequent counselling sessions provided by trained Dietitians, provision of educational resources and key food items consistent with a MedDiet (e.g., EVOO, legumes and nuts). As such, it remains unknown as to whether long-term adherence is possible, especially in non-Mediterranean populations, without adequate educational resources and support to help facilitate compliance ⁽¹⁸¹⁾. Additionally, literature suggests a need for developing strategies

aimed at enhancing skills related to goal-setting and self-efficacy for sustained dietary adherence ^(30, 181-183). A previous cross-sectional analysis of $n = 606$ Australian adults identified a number of important barriers towards adherence and uptake to a MedDiet, including knowledge, motivation, affordability, time, and suitability ⁽¹⁸⁴⁾. In the context of PCOS, Moran et al. ⁽¹⁸⁵⁾ used cross-sectional data from the Australian Longitudinal Study on Women's Health (ALSWH) and reported that women with PCOS were more likely to consume a dietary pattern consistent with MedDiet principles, suggesting there is potential for acceptability of a MedDiet in PCOS. Nevertheless, feasibility and acceptability studies exploring the adherence to a MedDiet in PCOS are scant.

Future direction and conclusions

Given the inherent complexity in the pathophysiology of PCOS, the precise mechanisms related to how a MedDiet attenuates cardiometabolic, reproductive and psychological features of PCOS remains in an enigma. At present, evidence from clinical trials is limited but emerging ⁽¹⁸⁶⁾. Notably, ongoing studies, including those listed on clinical trials registries, investigating the efficacy of a MedDiet intervention on PCOS is scant. Our group is currently investigating the efficacy of a MedDiet intervention on hormonal, metabolic and anthropometric measures, without the need for caloric restriction, in women with PCOS and overweight or obesity ⁽¹⁸⁶⁾. Given that IR is a prominent clinical feature in the pathophysiology of PCOS, a dietary approach based on key principles of a MedDiet, without the need for caloric restriction, may indeed represent a novel dietary intervention for women with and without obesity. Importantly, results from the aforementioned study will provide preliminary evidence which can be further explored using longer-term and adequately powered multimodal clinical trials investigating the feasibility of a MedDiet intervention, coupled with lifestyle related behaviour changes on outcomes pertinent in PCOS including cardiometabolic parameters, inflammatory markers, menstrual cyclicality, fertility and depressive symptoms. Of further importance, this work will also aim to identify the acceptability and feasibility of a MedDiet in women with PCOS. Given that there is limited literature on the feasibility and acceptability of a MedDiet intervention in women with PCOS, it is unknown whether there are unique barriers that would impede uptake and adherence within this population of women. Being able to identify and address potential barriers is an important step for informing effective and acceptable dietary interventions specific in clinical practice.

In conclusion, we have highlighted some observational evidence to support an inverse relationship between MedDiet adherence and PCOS features (namely IR and hyperandrogenemia). Nevertheless, well-designed clinical trials are needed to elucidate these findings. We have also explored the potential mechanistic benefits of the MedDiet on improving clinical features of PCOS which are likely related to the anti-inflammatory potential of the diet, reductions in oxidative stress and a higher intake of antioxidants. Although much of the proposed mechanisms are largely founded on individual anti-inflammatory bioactive constituents of a MedDiet (e.g., carotenoids, polyphenols and n-3 PUFAs), it is important to appreciate the important and complex synergistic relationship of nutrients and bioactive compounds within an existing dietary pattern. Whilst the current evidence is not yet sufficiently available to inform clinical practice, following a healthy dietary pattern, such as the MedDiet, to attenuate short and long-term symptoms associated PCOS has little known adverse consequences and may aid in reducing the longer-term risks associated with cardiometabolic diseases and reproductive and psychological dysfunction in women with PCOS.

References

1. Teede H, Misso M, Tassone EC *et al.* (2019) Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines. *Trends Endocrinol Metab* **30**, 467-478.
2. Joham AE, Norman RJ, Stener-Victorin E *et al.* (2022) Polycystic ovary syndrome. *The Lancet Diabetes & Endocrinology* **10**, 668-680.
3. Teede H, Deeks A Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Med* **8**, 41.
4. Teede HT, C.T.; Laven, J.S.E.; Dokras, A.; Moran, L.J.; Piltonen, T.; Costello, M.F.; Boivin, J.; Redman, L.; Boyle, J (2023) International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University: Melbourne, Australia.
5. Diamanti-Kandarakis E & Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev* **33**, 981-1030.
6. Fauser BCJMD, Tarlatzis BCMD, Rebar RWMD *et al.* (2012) Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam

- ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril* **97**, 28-38.e25.
7. de Groot PCM, Dekkers OM, Romijn JA *et al.* (2011) PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. *Hum Reprod Update* **17**, 495-500.
 8. Zhao L, Zhu Z, Lou H *et al.* (2016) Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. *Oncotarget* **7**, 33715-33721.
 9. Yadav A & Malhotra N (2022) Polycystic ovarian syndrome: diagnosis and management of related infertility. *Obstet Gynaecol Reprod Med* **32**, 197-204.
 10. Farland LV, Stern JE, Liu CL *et al.* (2022) Polycystic ovary syndrome and risk of adverse pregnancy outcomes: a registry linkage study from Massachusetts. *Hum Reprod* **37**, 2690-2699.
 11. Rees DA, Jenkins-Jones S Morgan CL (2016) Contemporary Reproductive Outcomes for Patients With Polycystic Ovary Syndrome: A Retrospective Observational Study. *J Clin Endocrinol Metab* **101**, 1664-1672.
 12. Teede HJ, Tay CT, Laven JJE *et al.* (2023) Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* **108**, 2447-2469.
 13. Lee IBA, Cooney LGMD, Saini SMD *et al.* (2016) Increased risk of disordered eating in polycystic ovary syndrome. *Fertil Steril* **107**, 796-802.
 14. Tay CT, Teede HJ, Hill B *et al.* (2019) Increased prevalence of eating disorders, low self-esteem, and psychological distress in women with polycystic ovary syndrome: a community-based cohort study. *Fertil Steril* **112**, 353-361.
 15. Cooney LG, Lee I, Sammel MD *et al.* (2017) High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod* **32**, 1075-1091.
 16. Damone AL, Joham AE, Loxton D *et al.* (2019) Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. *Psychol Med* **49**, 1510-1520.
 17. Deeks AA, Gibson-Helm ME Teede HJ (2010) Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. *Fertil Steril* **93**, 2421-2423.

18. Cassar S, Misso ML, Hopkins WG *et al.* (2016) Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. *Hum Reprod* **31**, 2619-2631.
19. Moghetti P & Tosi F (2021) Insulin resistance and PCOS: chicken or egg? *J Endocrinol Invest* **44**, 233-244.
20. Stepto NK, Moreno-Asso A, McIlvenna LC *et al.* (2019) Molecular Mechanisms of Insulin Resistance in Polycystic Ovary Syndrome: Unraveling the Conundrum in Skeletal Muscle? *J Clin Endocrinol Metab* **104**, 5372-5381.
21. Deswal R, Narwal V, Dang A *et al.* (2020) The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. *J Hum Reprod Sci* **13**, 261-271.
22. Lim SS, Davies MJ, Norman RJ *et al.* (2012) Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update* **18**, 618-637.
23. Lim SS, Norman RJ, Davies MJ *et al.* (2013) The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. *Obes Rev* **14**, 95-109.
24. Wolf WM, Wattick RA, Kinkade ON *et al.* (2018) The Current Description and Future Need for Multidisciplinary PCOS Clinics. *J Clin Med* **7**.
25. Moran LJ, Pasquali R, Teede HJ *et al.* (2009) Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. *Fertil Steril* **92**, 1966-1982.
26. Williams T, Mortada R Porter S (2016) Diagnosis and treatment of polycystic ovary syndrome. *Am Fam Physician* **94**, 106-113.
27. Teede HJ, Misso ML, Costello MF *et al.* (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertil Steril* **110**, 364-379.
28. Kataoka J, Tassone EC, Misso M *et al.* (2017) Weight Management Interventions in Women with and without PCOS: A Systematic Review. *Nutrients* **9**.
29. Moran LJ, Ko H, Misso M *et al.* (2013) Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines†. *Hum Reprod Update* **19**, 432-432.
30. Teede HJ, Misso ML, Deeks AA *et al.* (2011) Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. *Med J Aust* **195**, S65.

31. Clifford D, Ozier A, Bundros J *et al.* (2015) Impact of Non-Diet Approaches on Attitudes, Behaviors, and Health Outcomes: A Systematic Review. *J Nutr Educ Behav* **47**, 143-155.e141.
32. Willett WC, Sacks F, Trichopoulou A *et al.* (1995) Mediterranean diet pyramid: a cultural model for healthy eating. *The American Journal of Clinical Nutrition* **61**, 1402S-1406S.
33. Noah A & Truswell AS (2001) There are many Mediterranean diets. *Asia Pac J Clin Nutr* **10**, 2-9.
34. Trichopoulou A, Martinez-Gonzalez MA, Tong TY *et al.* (2014) Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. *BMC Med* **12**, 112.
35. Agnoli C, Sieri S, Ricceri F *et al.* (2018) Adherence to a Mediterranean diet and long-term changes in weight and waist circumference in the EPIC-Italy cohort. *Nutr Diabetes* **8**, 22-22.
36. Bendall CL, Mayr HL, Opie RS *et al.* (2018) Central obesity and the Mediterranean diet: A systematic review of intervention trials. *Crit Rev Food Sci Nutr* **58**, 3070-3084.
37. Ventriglio A, Sancassiani F, Contu MP *et al.* (2020) Mediterranean Diet and its Benefits on Health and Mental Health: A Literature Review. *Clin Pract Epidemiol Ment Health* **16**, 156-164.
38. Stepto NK, Cassar S, Joham AE *et al.* (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. *Hum Reprod* **28**, 777-784.
39. Anagnostis P, Tarlatzis BC, Kauffman RP (2018) Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. *Metabol* **86**, 33-43.
40. Legro RS, Kusanman AR, Dodson WC *et al.* (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* **84**, 165-169.
41. Kakoly NS, Khomami MB, Joham AE *et al.* (2018) Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. *Hum Reprod Update* **24**, 455-467.
42. Diamanti-Kandarakis E & Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Trends Mol Med* **12**, 324-332.

43. Pereira SS & Alvarez-Leite JI (2014) Low-grade inflammation, obesity, and diabetes. *Current obesity reports* **3**, 422-431.
44. Maiorino M, Bellastella G, Giugliano D *et al.* (2018) From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. *J Endocrinol Invest* **41**, 1249-1258.
45. Thomann R, Rossinelli N, Keller U *et al.* (2008) Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. *Gynecol Endocrinol* **24**, 199-206.
46. Balen AH & Rutherford AJ (2007) Managing anovulatory infertility and polycystic ovary syndrome. *BMJ* **335**, 663-666.
47. Melo AS, Ferriani RA Navarro PA (2015) Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. *Clinics (Sao Paulo)* **70**, 765-769.
48. Azziz R, Carmina E, Dewailly D *et al.* (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril* **91**, 456-488.
49. Nanba AT, Rege J, Ren J *et al.* (2019) 11-Oxygenated C19 Steroids Do Not Decline With Age in Women. *J Clin Endocrinol Metab* **104**, 2615-2622.
50. O'Reilly MW, Kempegowda P, Jenkinson C *et al.* (2017) 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* **102**, 840-848.
51. Zeng X, Xie Y-j, Liu Y-t *et al.* (2020) Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. *Clin Chim Acta* **502**, 214-221.
52. Alpañés M, Fernández-Durán E Escobar-Morreale HF (2012) Androgens and polycystic ovary syndrome. *Expert Rev Endocrinol Metab* **7**, 91-102.
53. Pierre A, Taieb J, Giton F *et al.* (2017) Dysregulation of the Anti-Müllerian Hormone System by Steroids in Women With Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* **102**, 3970-3978.
54. Xu F, Liu R Cao X (2017) Hyperandrogenism stimulates inflammation and promote apoptosis of cumulus cells. *Cell Mol Biol (Noisy-le-grand)* **63**, 64-68.

55. Lim JJ, Han CY, Lee DR *et al.* (2017) Ring Finger Protein 6 Mediates Androgen-Induced Granulosa Cell Proliferation and Follicle Growth via Modulation of Androgen Receptor Signaling. *Endocrinology* **158**, 993-1004.
56. Cadagan D, Khan R Amer S (2016) Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. *Reprod Biol* **16**, 53-60.
57. Rice S, Christoforidis N, Gadd C *et al.* (2005) Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. *Hum Reprod* **20**, 373-381.
58. Jena D, Choudhury AK, Mangaraj S *et al.* (2018) Study of Visceral and Subcutaneous Abdominal Fat Thickness and Its Correlation with Cardiometabolic Risk Factors and Hormonal Parameters in Polycystic Ovary Syndrome. *Indian J Endocrinol Metab* **22**, 321-327.
59. Lazúrová I, Lazúrová Z, Figurová J *et al.* (2019) Relationship between steroid hormones and metabolic profile in women with polycystic ovary syndrome. *Physiol Res* **68**, 457-465.
60. Bou Nemer L, Shi H, Carr BR *et al.* (2019) Effect of Body Weight on Metabolic Hormones and Fatty Acid Metabolism in Follicular Fluid of Women Undergoing In Vitro Fertilization: A Pilot Study. *Reprod Sci* **26**, 404-411.
61. Li Y, Lin H, Pan P *et al.* (2018) Impact of Central Obesity on Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization. *Biores Open Access* **7**, 116-122.
62. Rehman R, Mehmood M, Ali R *et al.* (2018) Influence of body mass index and polycystic ovarian syndrome on ICSI/IVF treatment outcomes: A study conducted in Pakistani women. *Int J Reprod Biomed* **16**, 529-534.
63. Orisaka M, Mizutani T, Miyazaki Y *et al.* (2023) Chronic low-grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging. *Front Endocrinol (Lausanne)* **14**, 1324429.
64. Gonzalez MB, Lane M, Knight EJ *et al.* (2018) Inflammatory markers in human follicular fluid correlate with lipid levels and Body Mass Index. *J Reprod Immunol* **130**, 25-29.
65. Rostamtabar M, Esmailzadeh S, Tourani M *et al.* (2021) Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome. *J Cell Physiol* **236**, 824-838.

66. Rudnicka E, Suchta K, Grymowicz M *et al.* (2021) Chronic Low Grade Inflammation in Pathogenesis of PCOS. *Int J Mol Sci* **22**.
67. Silva JRV, Lima FEO, Souza ALP *et al.* (2020) Interleukin-1 β and TNF- α systems in ovarian follicles and their roles during follicular development, oocyte maturation and ovulation. *Zygote* **28**, 270-277.
68. Qiao J & Feng HL (2011) Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. *Hum Reprod Update* **17**, 17-33.
69. Velez LM, Seldin M Motta AB (2021) Inflammation and reproductive function in women with polycystic ovary syndrome†. *Biol Reprod* **104**, 1205-1217.
70. Xing L, Xu J, Wei Y *et al.* (2022) Depression in polycystic ovary syndrome: Focusing on pathogenesis and treatment. *Front Psychiatry* **13**, 1001484.
71. Joseph DN & Whirledge S (2017) Stress and the HPA Axis: Balancing Homeostasis and Fertility. *Int J Mol Sci* **18**.
72. Chaudhari N, Dawalbhakta M Nampoothiri L (2018) GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. *Reprod Biol Endocrinol* **16**, 37.
73. Xing L, Xu J, Wei Y *et al.* (2022) Depression in polycystic ovary syndrome: focusing on pathogenesis and treatment. *Frontiers in Psychiatry* **13**, 1001484.
74. Singh MK, Leslie SM, Packer MM *et al.* (2019) Brain and behavioral correlates of insulin resistance in youth with depression and obesity. *Horm Behav* **108**, 73-83.
75. Aboeldalyl S, James C, Seyam E *et al.* (2021) The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis. *Int J Mol Sci* **22**.
76. Black PH (2003) The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. *Brain Behav Immun* **17**, 350-364.
77. Howren MB, Lamkin DM Suls J (2009) Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis. *Psychosom Med* **71**.
78. Greenwood EA, Pasch LA, Cedars MI *et al.* (2018) Insulin resistance is associated with depression risk in polycystic ovary syndrome. *Fertil Steril* **110**, 27-34.
79. Kolhe JV, Chhipa AS, Butani S *et al.* (2022) PCOS and Depression: Common Links and Potential Targets. *Reprod Sci* **29**, 3106-3123.

80. Dokras A, Clifton S, Futterweit W *et al.* (2012) Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril* **97**, 225-230.e222.
81. Himelein MJ & Thatcher SS (2006) Polycystic ovary syndrome and mental health: A review. *Obstet Gynecol Surv* **61**, 723-732.
82. Janssen OE, Hahn S, Tan S *et al.* (2008) Mood and sexual function in polycystic ovary syndrome. *Semin Reprod Med* **26**, 45-52.
83. Jones GL, Hall JM, Balen AH *et al.* (2008) Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. *Hum Reprod Update* **14**, 15-25.
84. Kerchner A, Lester W, Stuart SP *et al.* (2009) Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. *Fertil Steril* **91**, 207-212.
85. Lee I, Cooney LG, Saini S *et al.* (2019) Increased odds of disordered eating in polycystic ovary syndrome: a systematic review and meta-analysis. *Eat Weight Disord* **24**, 787-797.
86. Thannickal A, Brutocao C, Alsawas M *et al.* (2020) Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. *Clin Endocrinol (Oxf)* **92**, 338-349.
87. Skiba MA, Islam RM, Bell RJ *et al.* (2018) Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update* **24**, 694-709.
88. Feng Jg, Guo Y, Ma La *et al.* (2018) Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. *J Cosmet Dermatol* **17**, 511-517.
89. Chen TH, Chang SP, Tsai CF *et al.* (2004) Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. *Hum Reprod* **19**, 2313-2318.
90. Standeven LR, Hannan K, Singh B *et al.* (2023) Polycystic Ovary Syndrome: A Guide for Psychiatric Providers. *Advances in Psychiatry and Behavioral Health*.
91. Karjula S, Morin-Papunen L, Franks S *et al.* (2020) Population-based Data at Ages 31 and 46 Show Decreased HRQoL and Life Satisfaction in Women with PCOS Symptoms. *J Clin Endocrinol Metab* **105**, 1814-1826.

92. Barrea L, Arnone A, Annunziata G *et al.* (2019) Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). *Nutrients* **11**.
93. Cutillas-Tolín A, Areñese-Gonzalo JJ, Mendiola J *et al.* (2021) Are Dietary Indices Associated with Polycystic Ovary Syndrome and Its Phenotypes? A Preliminary Study. *Nutrients* **13**.
94. Barrea L, Muscogiuri G, Pugliese G *et al.* (2021) Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. *Nutrients* **13**, 3925.
95. Obeid CA, Gubbels JS, Jaalouk D *et al.* (2022) Adherence to the Mediterranean diet among adults in Mediterranean countries: A systematic literature review. *Eur J Nutr* **61**, 3327-3344.
96. Zaragoza-Martí A, Cabañero-Martínez MJ, Hurtado-Sánchez JA *et al.* (2018) Evaluation of Mediterranean diet adherence scores: a systematic review. *BMJ open* **8**, e019033.
97. Milte CM & McNaughton SA (2016) Dietary patterns and successful ageing: a systematic review. *Eur J Nutr* **55**, 423-450.
98. Chiriaco M, Tubili C, Bo S *et al.* (2023) Critical evaluation of the questionnaires assessing adherence to the Mediterranean diet that are based on servings. *Nutr Metab Cardiovasc Dis* **33**, 724-736.
99. Mei S, Ding J, Wang K *et al.* (2022) Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients. *Front Nutr* **9**, 876620.
100. Lim S, Norman RJ, Davies M *et al.* (2013) The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. *Obes Rev* **14**, 95-109.
101. Lim SS, Hutchison SK, Van Ryswyk E *et al.* (2019) Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev*.
102. Moran LJ, Hutchison SK, Norman RJ *et al.* (2011) Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev*, Cd007506.
103. Moran LJ, Noakes M, Clifton P *et al.* (2019) Predictors of Lifestyle Intervention Attrition or Weight Loss Success in Women with Polycystic Ovary Syndrome Who Are Overweight or Obese. *Nutrients* **11**, 492.

104. Foscolou A, Papandreou P, Gioxari A *et al.* (2024) Optimizing Dietary Habits in Adolescents with Polycystic Ovary Syndrome: Personalized Mediterranean Diet Intervention via Clinical Decision Support System—A Randomized Controlled Trial. *Children* **11**, 635.
105. Abodi M, De Cosmi V, Parazzini F *et al.* (2022) Omega-3 fatty acids dietary intake for oocyte quality in women undergoing assisted reproductive techniques: A systematic review. *Eur J Obstet Gynecol Reprod Biol* **275**, 97-105.
106. Grosso G, Godos J, Currenti W *et al.* (2022) The Effect of Dietary Polyphenols on Vascular Health and Hypertension: Current Evidence and Mechanisms of Action. *Nutrients* **14**.
107. Winiarska-Mieczan A, Kwiecień M, Jachimowicz-Rogowska K *et al.* (2023) Anti-Inflammatory, Antioxidant, and Neuroprotective Effects of Polyphenols-Polyphenols as an Element of Diet Therapy in Depressive Disorders. *Int J Mol Sci* **24**.
108. Estruch R, Ros E, Salas-Salvadó J *et al.* (2018) Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med* **378**, e34.
109. Salas-Salvadó J, Bulló M, Estruch R *et al.* (2014) Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. *Ann Intern Med* **160**, 1-10.
110. Delgado-Lista J, Alcalá-Díaz JF, Torres-Peña JD *et al.* (2022) Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *The Lancet* **399**, 1876-1885.
111. Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A *et al.* (2020) Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial. *PLoS Med* **17**, e1003282.
112. Galié S, García-Gavilán J, Papandreou C *et al.* (2021) Effects of Mediterranean Diet on plasma metabolites and their relationship with insulin resistance and gut microbiota composition in a crossover randomized clinical trial. *Clinical Nutrition* **40**, 3798-3806.
113. Esposito K, Marfella R, Ciotola M *et al.* (2004) Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA* **292**, 1440-1446.

114. Salas-Salvadó J, Díaz-López A, Ruiz-Canela M *et al.* (2019) Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. *Diabetes Care* **42**, 777-788.
115. Itsiopoulos C, Brazionis L, Kaimakamis M *et al.* (2011) Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. *Nutr Metab Cardiovasc Dis* **21**, 740-747.
116. Esposito K, Maiorino MI, Petrizzo M *et al.* (2014) The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial. *Diabetes Care* **37**, 1824-1830.
117. Gutierrez-Mariscal FM, Cardelo MP, de La Cruz S *et al.* (2021) Reduction in circulating advanced glycation end products by mediterranean diet is associated with increased likelihood of type 2 diabetes remission in patients with coronary heart disease: from the cordioprev study. *Mol Nutr Food Res* **65**, 1901290.
118. Stephenson J, Heslehurst N, Hall J *et al.* (2018) Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. *The Lancet* **391**, 1830-1841.
119. Gaskins AJ, Nassan FL, Chiu Y-H *et al.* (2019) Dietary patterns and outcomes of assisted reproduction. *Am J Obstet Gynecol* **220**, 567. e561-567. e518.
120. Karayiannis D, Kontogianni MD, Mendorou C *et al.* (2018) Adherence to the Mediterranean diet and IVF success rate among non-obese women attempting fertility. *Hum Reprod* **33**, 494-502.
121. Sun H, Lin Y, Lin D *et al.* (2019) Mediterranean diet improves embryo yield in IVF: a prospective cohort study. *Reprod Biol Endocrinol* **17**, 1-7.
122. Noli SA, Ferrari S, Ricci E *et al.* (2023) Adherence to the Mediterranean diet and the risk of unexpected poor response to ovarian stimulation in IVF cycles. *Reprod Biomed Online* **47**, 77-83.
123. Ricci E, Bravi F, Noli S *et al.* (2019) Mediterranean diet and outcomes of assisted reproduction: an Italian cohort study. *Am J Obstet Gynecol* **221**, 627. e621-627. e614.
124. Barbosa G, de Sá LBPC, Rocha DRTW *et al.* (2016) Polycystic ovary syndrome (PCOS) and fertility. *Open Journal of Endocrine and Metabolic Diseases* **6**, 58-65.

125. Onieva-Zafra MD, Fernández-Martínez E, Abreu-Sánchez A *et al.* (2020) Relationship between diet, menstrual pain and other menstrual characteristics among Spanish students. *Nutrients* **12**, 1759.
126. Altun A, Brown H, Szoeki C *et al.* (2019) The Mediterranean dietary pattern and depression risk: A systematic review. *Neurology, Psychiatry and Brain Research* **33**, 1-10.
127. Shafiei F, Salari-Moghaddam A, Larijani B *et al.* (2019) Adherence to the Mediterranean diet and risk of depression: a systematic review and updated meta-analysis of observational studies. *Nutr Rev* **77**, 230-239.
128. Jacka FN, O'Neil A, Opie R *et al.* (2017) A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). *BMC Med* **15**, 23.
129. Parletta N, Zarnowiecki D, Cho J *et al.* (2019) A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). *Nutr Neurosci* **22**, 474-487.
130. Bizzozero-Peroni B, Martínez-Vizcaíno V, Fernández-Rodríguez R *et al.* (2024) The impact of the Mediterranean diet on alleviating depressive symptoms in adults: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev*, **176**.
131. Braga DPAF, Halpern G, Setti AS *et al.* (2015) The impact of food intake and social habits on embryo quality and the likelihood of blastocyst formation. *Reprod Biomed Online* **31**, 30-38.
132. Casas R, Sacanella E, Urpí-Sardà M *et al.* (2016) Long-term immunomodulatory effects of a Mediterranean diet in adults at high risk of cardiovascular disease in the PREvención con DIeta MEDiterránea (PREDIMED) randomized controlled trial. *The Journal of nutrition* **146**, 1684-1693.
133. Firns S, Cruzat VF, Keane KN *et al.* (2015) The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: a review and presentation of original data. *Reprod Biol Endocrinol* **13**, 1-13.
134. Garruti G, Depalo R De Angelis M (2019) Weighing the impact of diet and lifestyle on female reproductive function. *Curr Med Chem* **26**, 3584-3592.
135. Moran LJ, Tsagareli V, Noakes M *et al.* (2016) Altered preconception fatty acid intake is associated with improved pregnancy rates in overweight and obese women undertaking in vitro fertilisation. *Nutrients* **8**, 10.

136. Chrysohoou C, Panagiotakos DB, Pitsavos C *et al.* (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. *J Am Coll Cardiol* **44**, 152-158.
137. Luisi MLE, Lucarini L, Biffi B *et al.* (2019) Effect of Mediterranean diet enriched in high quality extra virgin olive oil on oxidative stress, inflammation and gut microbiota in obese and normal weight adult subjects. *Front Pharmacol* **10**, 1366.
138. Richard C, Couture P, Desroches S *et al.* (2013) Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. *Obesity* **21**, 51-57.
139. Sureda A, Bibiloni MdM, Julibert A *et al.* (2018) Adherence to the mediterranean diet and inflammatory markers. *Nutrients* **10**, 62.
140. González-Gallego J, García-Mediavilla MV, Sánchez-Campos S *et al.* (2010) Fruit polyphenols, immunity and inflammation. *Br J Nutr* **104**, S15-S27.
141. Yahfoufi N, Alsadi N, Jambi M *et al.* (2018) The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. *Nutrients* **10**.
142. Fiedor J & Burda K (2014) Potential role of carotenoids as antioxidants in human health and disease. *Nutrients* **6**, 466-488.
143. Liu RH (2013) Health-promoting components of fruits and vegetables in the diet. *Adv Nutr* **4**, 384S-392S.
144. Nani A, Murtaza B, Sayed Khan A *et al.* (2021) Antioxidant and anti-inflammatory potential of polyphenols contained in mediterranean diet in obesity: Molecular mechanisms. *Molecules* **26**, 985.
145. Carpi S, Scoditti E, Massaro M *et al.* (2019) The extra-virgin olive oil polyphenols oleocanthal and oleacein counteract inflammation-related gene and miRNA expression in adipocytes by attenuating NF- κ B activation. *Nutrients* **11**, 2855.
146. Bach Knudsen KE, Lærke HN, Hedemann MS *et al.* (2018) Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. *Nutrients* **10**, 1499.
147. Elce A, Amato F, Zarrilli F *et al.* (2017) Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells. *Beneficial Microbes* **8**, 841-847.

148. McLoughlin RF, Berthon BS, Jensen ME *et al.* (2017) Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. *The American journal of clinical nutrition* **106**, 930-945.
149. Upritchard JE, Sutherland W Mann JI (2000) Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. *Diabetes Care* **23**, 733-738.
150. Wannamethee SG, Lowe GD, Rumley A *et al.* (2006) Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. *The American journal of clinical nutrition* **83**, 567-574.
151. Mantzioris E, Muhlhausler BS Villani A (2022) Impact of the Mediterranean Dietary pattern on n-3 fatty acid tissue levels—A systematic review. *Prostaglandins, Leukotrienes and Essential Fatty Acids* **176**, 102387.
152. Natto ZS, Yaghmoor W, Alshaeri HK *et al.* (2019) Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients: a systematic review and meta-analysis. *Sci Rep* **9**, 18867.
153. Rangel-Huerta OD, Aguilera CM, Mesa MD *et al.* (2012) Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomarkers: a systematic review of randomised clinical trials. *Br J Nutr* **107**, S159-S170.
154. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Br J Clin Pharmacol* **75**, 645-662.
155. Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochem Soc Trans* **45**, 1105-1115.
156. Calder PC (2015) Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* **1851**, 469-484.
157. Bhaswant M, Poudyal H Brown L (2015) Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. *J Nutr Biochem* **26**, 571-584.
158. Sanchez-Rodriguez E, Vazquez-Aguilar LA, Biel-Glesson S *et al.* (2021) May bioactive compounds from the olive fruit improve the postprandial insulin response in healthy adults? *J Funct Foods* **83**, 104561.
159. Thombare K, Ntika S, Wang X *et al.* (2017) Long chain saturated and unsaturated fatty acids exert opposing effects on viability and function of GLP-1-producing cells: mechanisms of lipotoxicity. *PLoS One* **12**, e0177605.

160. Dhanya R, Arya A, Nisha P *et al.* (2017) Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line. *Front Pharmacol* **8**, 257542.
161. Eid HM, Martineau LC, Saleem A *et al.* (2010) Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant *Vaccinium vitis-idaea*. *Mol Nutr Food Res* **54**, 991-1003.
162. Hussain T, Tan B, Murtaza G *et al.* (2020) Flavonoids and type 2 diabetes: Evidence of efficacy in clinical and animal studies and delivery strategies to enhance their therapeutic efficacy. *Pharmacol Res* **152**, 104629.
163. Alesi S, Villani A, Mantzioris E *et al.* (2022) Anti-inflammatory diets in fertility: an evidence review. *Nutrients* **14**, 3914.
164. Al-Gubory KH, Fowler PA, Garrel C (2010) The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. *The international journal of biochemistry & cell biology* **42**, 1634-1650.
165. Anckaert E, Romero S, Adriaenssens T *et al.* (2010) Effects of low methyl donor levels in culture medium during mouse follicle culture on oocyte imprinting establishment. *Biol Reprod* **83**, 377-386.
166. Barcikowska Z, Rajkowska-Labon E, Grzybowska ME *et al.* (2020) Inflammatory markers in dysmenorrhea and therapeutic options. *Int J Environ Res Public Health* **17**, 1191.
167. Trebble TM, Wootton SA, Miles EA *et al.* (2003) Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. *The American journal of clinical nutrition* **78**, 376-382.
168. Mohammadi MM, Mirjalili R, Faraji A (2022) The impact of omega-3 polyunsaturated fatty acids on primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. *Eur J Clin Pharmacol* **78**, 721-731.
169. Snipe RM, Brelis B, Kappas C *et al.* (2024) Omega-3 long chain polyunsaturated fatty acids as a potential treatment for reducing dysmenorrhoea pain: Systematic literature review and meta-analysis. *Nutr Diet* **81**, 94-106.
170. Marx W, Lane M, Hockey M *et al.* (2021) Diet and depression: exploring the biological mechanisms of action. *Mol Psychiatry* **26**, 134-150.

171. Bayes J, Schloss J Sibbritt D (2020) Effects of polyphenols in a Mediterranean diet on symptoms of depression: a systematic literature review. *Adv Nutr* **11**, 602-615.
172. Fazel Nabavi S, M Dean O, Turner A *et al.* (2015) Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols? *Curr Med Chem* **22**, 343-351.
173. Holsboer F & Ising M (2010) Stress hormone regulation: biological role and translation into therapy. *Annu Rev Psychol* **61**, 81-109.
174. Miller AH, Maletic V Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol Psychiatry* **65**, 732-741.
175. Berding K, Vlckova K, Marx W *et al.* (2021) Diet and the microbiota–gut–brain axis: sowing the seeds of good mental health. *Adv Nutr* **12**, 1239-1285.
176. Davis CR, Bryan J, Hodgson JM *et al.* (2015) Older Australians can adhere to a traditional Mediterranean style diet over two weeks: a pilot dietary intervention study. *BMC Nutrition* **1**, 1-10.
177. Zacharia K, Patterson AJ, English C *et al.* (2020) Feasibility of the AusMed diet program: translating the Mediterranean diet for older Australians. *Nutrients* **12**, 1044.
178. Appleton KM, McEvoy CT, Lloydwin C *et al.* (2023) A peer support dietary change intervention for encouraging adoption and maintenance of the Mediterranean diet in a non-Mediterranean population (TEAM-MED): lessons learned and suggested improvements. *Journal of Nutritional Science* **12**, e13.
179. Lara J, Turbett E, Mckeivic A *et al.* (2015) The Mediterranean diet among British older adults: Its understanding, acceptability and the feasibility of a randomised brief intervention with two levels of dietary advice. *Maturitas* **82**, 387-393.
180. Mantzioris E & Villani A (2019) Translation of a Mediterranean-Style Diet into the Australian Dietary Guidelines: A Nutritional, Ecological and Environmental Perspective. *Nutrients* **11**.
181. Arentz S, Smith CA, Abbott J *et al.* (2021) Perceptions and experiences of lifestyle interventions in women with polycystic ovary syndrome (PCOS), as a management strategy for symptoms of PCOS. *BMC Womens Health* **21**, 107.
182. Humphreys L & Costarelli V (2008) Implementation of dietary and general lifestyle advice among women with polycystic ovarian syndrome. *The journal of the Royal Society for the Promotion of Health* **128**, 190-195.
183. Lim S, Smith CA, Costello MF *et al.* (2020) Health literacy needs in weight management of women with Polycystic Ovary Syndrome. *Health Promot J Austr.*

184. Scannell N, Villani A, Mantzioris E *et al.* (2020) Understanding the Self-Perceived Barriers and Enablers toward Adopting a Mediterranean Diet in Australia: An Application of the Theory of Planned Behaviour Framework. *Int J Environ Res Public Health* **17**.
185. Moran LJ, Grieger JA, Mishra GD *et al.* (2015) The Association of a Mediterranean-Style Diet Pattern with Polycystic Ovary Syndrome Status in a Community Cohort Study. *Nutrients* **7**, 8553-8564.
186. Scannell N, Moran L, Mantzioris E *et al.* (2022) Efficacy, Feasibility and Acceptability of a Mediterranean Diet Intervention on Hormonal, Metabolic and Anthropometric Measures in Overweight and Obese Women with Polycystic Ovary Syndrome: Study Protocol. *Metabolites* **12**.




Figure 1. The proposed mechanisms and benefits of a Mediterranean diet for features of Polycystic Ovary Syndrome.

IR insulin resistance, CVD cardiovascular disease, T2DM type 2 diabetes mellitus, WC waist circumference, IVF in vitro fertilization.

Table 1. Characteristics of studies investigating the Mediterranean diet on clinical features of Polycystic Ovary Syndrome

Author	Primary aim	Country of origin	Study design	Study population & sample size	Primary outcomes
Barrea et al 2019 ⁽⁹²⁾	To assess the association between MedDiet adherence and clinical severity of PCOS	Italy	Cross-sectional	<i>n</i> = 224 women (<i>n</i> = 112 with PCOS; <i>n</i> = 112 controls) aged 18-40 years, BMI 18.5-39.9 kg/m ² and free from underlying cardiometabolic disease	Greater adherence to a MedDiet was inversely associated with IR and hyperandrogenemia
Cutillas-Tolín et al 2021 ⁽⁹³⁾	To explore associations between diet quality indices and the presence of PCOS features	Spain	Case-control	<i>n</i> = 285 women (<i>n</i> = 126 with PCOS; <i>n</i> = 159 controls) aged 18-40 years	Adherence to a MedDiet was protective against clinical phenotypic features of PCOS, namely hyperandrogenism and oligo-anovulation
Barrea et al 2021 ⁽⁹⁴⁾	To characterize the determinants of the	Italy	Cross-sectional	<i>n</i> = 94 women with PCOS; aged 18-30 years,	Poor adherence to a MedDiet was

metabolic health status in obese women with PCOS

BMI ≥ 30 kg/m² and free from underlying cardiometabolic disease associated with a ‘metabolically unhealthy obesity’ as defined through evaluation of endocrine-metabolic profiles, inflammatory status, cardiometabolic indices and body composition parameters.

Mei et al 2022 ⁽⁹⁹⁾

To determine the therapeutic benefits of an energy-reduced low-CHO, Mediterranean-style diet, compared with a standard low-fat diet, on reproductive, endocrine and cardiometabolic parameters in overweight and obese patients with PCOS

China

Randomised control trial (12-week intervention)

$n = 59$ (low-CHO, MedDiet, $n = 29$; standard low-fat, $n = 30$) overweight (BMI ≥ 24 kg/m²) women with PCOS without underlying cardiometabolic disease, free from use of non-progesterone hormonal medication, insulin sensitisers or lipid lowering medications within the previous 3 months and not planning for pregnancy or no use of contraceptive pill during the intervention period

Both dietary interventions were effective in improving anthropometric, reproductive and cardiometabolic parameters; however, the energy restricted low-CHO Mediterranean-style diet was superior in restoring menstrual regularity, lowering body weight, waist circumference and improving fasting blood glucose, insulin sensitivity, total testosterone and luteinizing hormone

Foscolou et al
2024⁽¹⁰⁴⁾

To investigate the potential benefits of a personalized MedDiet intervention, compared with a standard lifestyle intervention, on optimizing nutritional status and attenuating symptoms of anxiety in adolescent girls diagnosed with PCOS

Greece

Randomised control trial
(12-week intervention)

$n = 40$ (MedDiet, $n = 20$; standard lifestyle intervention, $n = 20$) adolescent females aged 15–17 years free from severe illness, psychiatric disorders, following a specific diet within the previous 5 years or use of nutritional supplements within the previous 6 months.

A personalised MedDiet intervention, when compared against a standard lifestyle intervention, was more effective at improving diet quality (i.e., decreased energy intake, total fat, SFA, and increased intake of dietary fibre and MUFA), attenuating symptoms of anxiety, reductions in body weight, body fat and triglycerides.

Abbreviations: MedDiet, Mediterranean diet; PCOS, polycystic ovary syndrome; IR, insulin resistance; CHO, carbohydrate; SFA, saturated fatty acid; MUFA, monounsaturated fatty acid